Novo Nordisk Sees Modest Sales Impact in 2026 After U.S. Drug Price Cuts

This article first appeared on GuruFocus.

Novo Nordisk (NVO, Financials) said that it thinks global sales growth would slow down a little bit next year after agreeing to lower the prices of its blockbuster GLP-1 weight-loss medications for U.S. government health programs and those who pay cash. The company's new pricing contract is expected to have a negative low single-digit impact on global revenue in 2026. The change is part of a larger effort by the White House to make obesity treatments more widely available. It will cut monthly expenses for Medicare, Medicaid, and people who pay for their own care. Novo Nordisk noted that even though things are tough right now, it expects more patients to be able to get its Wegovy and Ozempic medications in the US, where demand for them is still robust. This will help the company develop in the long run. Analysts see the plan as a way for the business to solidify its leadership in the weight-management medicine sector by balancing pricing pressure and market expansion.

View Comments